Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stock Report

Market Cap: SEK 102.4b

Swedish Orphan Biovitrum Valuation

Is SOBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOBI (SEK298.2) is trading below our estimate of fair value (SEK1246.46)

Significantly Below Fair Value: SOBI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOBI?

Key metric: As SOBI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SOBI. This is calculated by dividing SOBI's market cap by their current earnings.
What is SOBI's PE Ratio?
PE Ratio29.1x
EarningsSEK 3.51b
Market CapSEK 102.41b

Price to Earnings Ratio vs Peers

How does SOBI's PE Ratio compare to its peers?

The above table shows the PE ratio for SOBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.3x
BIOG B BioGaia
31.4x16.6%SEK 10.6b
300122 Chongqing Zhifei Biological Products
18.9x45.1%CN¥70.7b
CAMX Camurus
125.9x83.1%SEK 33.5b
EXEL Exelixis
21.1x15.6%US$9.8b
SOBI Swedish Orphan Biovitrum
29.1x20.2%SEK 102.4b

Price-To-Earnings vs Peers: SOBI is good value based on its Price-To-Earnings Ratio (29.1x) compared to the peer average (49.4x).

Price to Earnings Ratio vs Industry

How does SOBI's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SOBI 29.1xIndustry Avg. 26.8xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SOBI is expensive based on its Price-To-Earnings Ratio (29.1x) compared to the European Biotechs industry average (26.8x).

Price to Earnings Ratio vs Fair Ratio

What is SOBI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOBI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.1x
Fair PE Ratio56.1x

Price-To-Earnings vs Fair Ratio: SOBI is good value based on its Price-To-Earnings Ratio (29.1x) compared to the estimated Fair Price-To-Earnings Ratio (56.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOBI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 298.20
SEK 360.36
+20.8%
11.0%SEK 410.00SEK 275.00n/a11
Nov ’25SEK 329.40
SEK 351.27
+6.6%
11.2%SEK 410.00SEK 275.00n/a11
Oct ’25SEK 309.00
SEK 325.55
+5.4%
8.9%SEK 370.00SEK 250.00n/a11
Sep ’25SEK 320.00
SEK 328.00
+2.5%
8.5%SEK 370.00SEK 250.00n/a11
Aug ’25SEK 278.00
SEK 328.30
+18.1%
8.9%SEK 370.00SEK 250.00n/a10
Jul ’25SEK 285.80
SEK 329.60
+15.3%
6.2%SEK 370.00SEK 285.00n/a10
Jun ’25SEK 282.40
SEK 320.00
+13.3%
9.4%SEK 370.00SEK 252.00n/a10
May ’25SEK 285.40
SEK 317.22
+11.2%
9.8%SEK 370.00SEK 252.00n/a9
Apr ’25SEK 267.20
SEK 317.70
+18.9%
9.6%SEK 370.00SEK 252.00n/a10
Mar ’25SEK 260.80
SEK 317.91
+21.9%
9.2%SEK 370.00SEK 252.00n/a11
Feb ’25SEK 278.00
SEK 316.20
+13.7%
8.0%SEK 345.00SEK 252.00n/a10
Jan ’25SEK 267.00
SEK 297.00
+11.2%
6.0%SEK 325.00SEK 252.00n/a10
Dec ’24SEK 250.60
SEK 293.00
+16.9%
7.0%SEK 325.00SEK 252.00n/a10
Nov ’24SEK 234.00
SEK 287.45
+22.8%
10.0%SEK 325.00SEK 222.00SEK 329.4011
Oct ’24SEK 223.40
SEK 285.55
+27.8%
10.0%SEK 325.00SEK 222.00SEK 309.0011
Sep ’24SEK 211.00
SEK 284.18
+34.7%
10.1%SEK 325.00SEK 222.00SEK 320.0011
Aug ’24SEK 205.80
SEK 288.27
+40.1%
9.8%SEK 325.00SEK 222.00SEK 278.0011
Jul ’24SEK 210.40
SEK 286.80
+36.3%
10.4%SEK 325.00SEK 216.00SEK 285.8010
Jun ’24SEK 212.00
SEK 285.80
+34.8%
10.6%SEK 325.00SEK 216.00SEK 282.4010
May ’24SEK 249.40
SEK 287.20
+15.2%
11.5%SEK 325.00SEK 211.00SEK 285.4010
Apr ’24SEK 241.50
SEK 269.78
+11.7%
9.6%SEK 305.00SEK 211.00SEK 267.209
Mar ’24SEK 240.40
SEK 269.78
+12.2%
9.6%SEK 305.00SEK 211.00SEK 260.809
Feb ’24SEK 230.70
SEK 253.56
+9.9%
12.5%SEK 305.00SEK 203.00SEK 278.009
Jan ’24SEK 215.70
SEK 249.10
+15.5%
11.9%SEK 295.00SEK 200.00SEK 267.0010
Dec ’23SEK 226.70
SEK 250.60
+10.5%
12.2%SEK 295.00SEK 200.00SEK 250.6010
Nov ’23SEK 206.20
SEK 250.60
+21.5%
12.2%SEK 295.00SEK 200.00SEK 234.0010

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

AstraZeneca

UK£154.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,392.50

7D

-1.0%

1Y

4.7%

Ascelia Pharma

SEK 252.2m

A biotech company, focuses on orphan oncology treatments in Sweden.

ACE

SEK 2.63

7D

-0.9%

1Y

-9.3%

Corline Biomedical

SEK 144.0m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.70

7D

-4.6%

1Y

-42.2%